RxDoctor Payments Data

Pamela Geary

Acute Care · Johnstown, PANPI 1003105362

Payments from drug & device makers

$1,127in general payments, 2019–2025

Across 40 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$215
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
  • Inari Medical, Inc.$138
  • E.r. Squibb & Sons, L.L.C.$132
  • Johnson & Johnson$112
  • Novartis$104
  • plus $228 from 9 others

What the payments were for

  • Food & beverage$1,03792%
  • Education$908%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,127 in reported general payments places this provider in the 80th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,713
Medicare patients
137
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban549$469,208
Repatha SureclickEvolocumab302$182,134
XareltoRivaroxaban137$114,701
JardianceEmpagliflozin83$77,674
EntrestoSacubitril/Valsartan80$66,584
MultaqDronedarone Hcl59$56,516
FarxigaDapagliflozin Propanediol29$31,132
Praluent PenAlirocumab39$24,342
BrilintaTicagrelor43$22,019
Atorvastatin Calcium746$13,674
Digoxin345$6,419
Ezetimibe259$6,138
Verapamil ErVerapamil Hcl176$5,395
Nifedipine ErNifedipine173$4,596
ClopidogrelClopidogrel Bisulfate328$4,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$112$114,701137 claims
NovartisEntresto$104$66,58480 claims
Sanofi-aventis U.S. LLCMultaq$49$56,51659 claims
AstraZenecaFarxiga, Brilinta$215$53,15172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →